Get started
Author

Akiko Yoshinaga

Observed name: A. Yoshinaga
ORCID: 0009-0002-2159-1164
Observed ORCID: 0009-0002-2159-1164
OpenAlex ID: A5016860642
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
2022 · Shilpa Prabhakar, Roberta L. Beauchamp, et al. · Molecular Therapy — Methods & Clinical Development · 19
Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines
2021 · Keisuke Taniguchi, Hiroaki Konishi, et al. · Scientific Reports · 13
PDF
Tracking human neurologic disease status in mouse brain/plasma using reporter-tagged, EV-associated biomarkers
2023 · Katia E. Maalouf, Christine A. Vaine, et al. · Molecular Therapy · 9
PDF
Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential
2024 · Sho Sato, Takahito Miura, et al. · Journal of Gynecologic Oncology · 2
PDF
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
2024 · Shilpa Prabhakar, Roberta L. Beauchamp, et al. · Molecular Therapy — Methods & Clinical Development
Comparison of Therapeutic Efficacy of Gene Therapy for Tuberous Sclerosis Type 2 with Standard of Care Everolimus in Preclinical Model (S14.002)
2023 · Edwina Abou Haidar, Shilpa Prabhakar, et al. · Neurology
Ex vivo cytotoxicity and in vivo anti-tumour activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
2019 · K. Hasegawa, K. Taniguchi, et al. · Annals of Oncology
PDF
A novel STAT3 inhibitor YHO-1701 inhibits ovarian and endometrial cancer cell growth, with augmented cytotoxicity in combination with an mTOR inhibitor
2019 · K. Hasegawa, A. Yoshinaga, et al. · Gynecologic Oncology
Works count: 8
Citation count: 43
H-index: 3
I10-index: 2
Year
Topic
Type